natürliche glp 1 agonisten GLP-1-Rezeptor-Agonist-Marktgröße, Anteil Mapping the effectiveness and risks

Studies are also underway for a spectrum of other conditions, including Phase 3 trials investigating non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), and obstructive sleep apnea (OSA), as well as mid-to-late stage trials exploring potential benefits in neurodegenerative disorders like Parkinsons disease

Beyond the options already discussed, several compounds in early-to-mid-stage development could reshape the landscape within the next two to five years

Santacruzamate A, HDAC2 inhibitor, 1 nM

These medication access solutions help patients navigate complex coverage requirements, obtain financial assistance, and adhere to their prescribed treatments

& Li, Y

doi: 10.1007/s00125-024-06273-7 [DOI] [PMC free article] [PubMed] [Google Scholar] 23